<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51852">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01770730</url>
  </required_header>
  <id_info>
    <org_study_id>LAMRCT</org_study_id>
    <nct_id>NCT01770730</nct_id>
  </id_info>
  <brief_title>A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients</brief_title>
  <acronym>LAMRCT</acronym>
  <official_title>A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Zimbabwe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NIMR - Mbeya Medical Research Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <authority>South Africa: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB
      diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with
      increasing illness severity and more advanced immunosuppression, thus offering the greatest
      potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4
      cell count less than 200). However, in the context of high rates of empiric treatment and
      the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip
      test is unknown. This study will investigate the impact of the urine LAM strip test. The
      study hypothesis is that the urine LAM strip test, when combined with standard TB
      diagnostics (smear microscopy and culture) will significantly improve TB treatment-related
      outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected
      hospitalized patients when compared to standard TB diagnostics alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All-cause mortality at 8-weeks after study enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in TB-related morbidity score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparative change in TB score between baseline and 8 weeks after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Karnofsky performance index</measure>
    <time_frame>Baseline and 8 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparative changes in the Karnofsky performance index between baseline and 8 weeks following enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Date of hospital discharge (max 8 weeks) minus date of admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is the number of days of hospital admission for enrolled patients up to a maximum of 8 weeks post enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of urine LAM strip test</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diagnostic accuracy (sensitivity, specificity, predictive values and likelihood ratios) of the urine LAM strip test using TB culture as the diagnostic reference standard</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>LAM plus standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urine LAM strip test</intervention_name>
    <description>This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment</description>
    <arm_group_label>LAM plus standard care</arm_group_label>
    <other_name>Determine TB urine LAM Antigen strip test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected (1x rapid HIV test positive)

          -  Considered TB suspect by attending doctor (must comprise  at least 1 of the
             following: current fever or cough, drenching night sweats, self-reported LOW)

          -  Illness severity sufficient to warrant hospitalization

          -  â‰¥18 years old

          -  Provision of informed consent

        Exclusion Criteria:

          -  HIV-uninfected

          -  Patients receiving any anti-TB medication in the 60 days prior to testing

          -  Unable to provide 30mls urine

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keertan Dheda, MD</last_name>
    <role>Study Director</role>
    <affiliation>UCT Lung Infection and Immunity Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Peter, MD</last_name>
    <phone>+27214066119</phone>
    <email>Jonny.Peter@uct.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keertan Dheda, MD PhD</last_name>
    <phone>+27214067654</phone>
    <email>Keertan.Dheda@uct.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7945</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Peter, MD</last_name>
      <phone>+27214066119</phone>
      <email>Jonny.Peter@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Jonathan Peter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keertan Dheda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grant Theron, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mbeya Medical Research Programme</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Clowes, MD</last_name>
      <phone>+255252503364</phone>
      <email>pclowes@mmrp.org</email>
    </contact>
    <investigator>
      <last_name>Michael Hoelscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Rachow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Clowes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duncan Chanda, MD</last_name>
      <phone>+260964100097</phone>
      <email>duncanchanda@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Duncan Chanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Mwaba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Zijenah, PhD</last_name>
      <phone>+2634791631</phone>
      <email>lzijenah@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lynn Zijenah, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <link>
    <url>http://www.lunginstitute.co.za/content/lung_infection.html</url>
    <description>UCT Lung Infection and Immunity website</description>
  </link>
  <reference>
    <citation>Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, Binder A, Meldau R, Hardy A, Dheda K. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012 Nov;40(5):1211-20. doi: 10.1183/09031936.00201711. Epub 2012 Feb 23. PubMed PMID: 22362849.</citation>
    <PMID>22362849</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012 Mar;12(3):201-9. doi: 10.1016/S1473-3099(11)70251-1. Epub 2011 Oct 17.</citation>
    <PMID>22015305</PMID>
  </reference>
  <reference>
    <citation>Peter JG, Theron G, Dheda K. Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infect Dis. 2012 Nov;12(11):825; author reply 826-7. doi: 10.1016/S1473-3099(12)70220-7.</citation>
    <PMID>23099073</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 15, 2013</lastchanged_date>
  <firstreceived_date>January 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Jonathan Peter</investigator_full_name>
    <investigator_title>Honorary consultant, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>urine LAM strip test</keyword>
  <keyword>diagnostics</keyword>
  <keyword>tuberculosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
